TC
NBIX icon

TownSquare Capital’s Neurocrine Biosciences NBIX Stock Holding History

TownSquare Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,124
Closed -$290K – 1739
2024
Q4 		$290K Buy
+2,124
New +$263K ﹤0.01% 1269
2023
Q2 		– Sell
-22,874
Closed -$2.32M – 1098
2023
Q1 		$2.32M Sell
22,874
-935
-4% -$97.3K 0.05% 300
2022
Q4 		$2.84M Sell
23,809
-2,679
-10% -$314K 0.07% 245
2022
Q3 		$2.81M Sell
26,488
-593
-2% -$60.2K 0.08% 214
2022
Q2 		$2.64M Buy
27,081
+2,378
+10% +$219K 0.07% 223
2022
Q1 		$2.32M Buy
24,703
+7,655
+45% +$649K 0.06% 258
2021
Q4 		$1.45M Sell
17,048
-863
-5% -$79.4K 0.04% 313
2021
Q3 		$1.72M Buy
17,911
+2,836
+19% +$268K 0.05% 280
2021
Q2 		$1.47M Buy
15,075
+3,748
+33% +$359K 0.05% 279
2021
Q1 		$1.1M Buy
11,327
+1,326
+13% +$139K 0.04% 284
2020
Q4 		$958K Buy
10,001
+4,262
+74% +$412K 0.04% 298
2020
Q3 		$557K Buy
+5,739
New +$664K 0.03% 292

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TownSquare Capital's NBIX Position: Q1 2025 in Review

TownSquare Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 2,124 shares — an estimated $290K sold.

TownSquare Capital first reported a position in NBIX in Q3 2020 and held it in 12 quarters. The position peaked at $2.84M in Q4 2022. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • TownSquare Capital reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • TownSquare Capital sold 2,124 Neurocrine Biosciences shares in Q1 2025, an estimated $290K.
  • TownSquare Capital first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 12 quarters.
  • TownSquare Capital's Neurocrine Biosciences position peaked at $2.84M in Q4 2022.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on TownSquare Capital's 13F filing for Q1 2025, filed 12 May 2025.